Revelation Stock Based Compensation vs Capital Expenditures Analysis
| REVB Stock | USD 0.36 0.01 2.86% |
Revelation Biosciences financial indicator trend analysis is much more than just breaking down Revelation Biosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Revelation Biosciences is a good investment. Please check the relationship between Revelation Biosciences Stock Based Compensation and its Capital Expenditures accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.
Stock Based Compensation vs Capital Expenditures
Stock Based Compensation vs Capital Expenditures Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Revelation Biosciences Stock Based Compensation account and Capital Expenditures. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Revelation Biosciences' Stock Based Compensation and Capital Expenditures is -0.31. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Revelation Biosciences, assuming nothing else is changed. The correlation between historical values of Revelation Biosciences' Stock Based Compensation and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Revelation Biosciences are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Stock Based Compensation i.e., Revelation Biosciences' Stock Based Compensation and Capital Expenditures go up and down completely randomly.
Correlation Coefficient | -0.31 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Capital Expenditures
Capital Expenditures are funds used by Revelation Biosciences to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Revelation Biosciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most indicators from Revelation Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Revelation Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.At present, Revelation Biosciences' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 94.48, whereas Selling General Administrative is forecasted to decline to about 4.3 M.
| 2018 | 2019 | 2023 | 2024 (projected) | Net Interest Income | 82.8M | 92.9M | 106.8M | 81.1M | Tax Provision | 9.4M | 11.6M | 13.3M | 11.2M |
Revelation Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Revelation Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Revelation Biosciences fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 22.7K | 4.6M | 2.0M | 5.5M | 12.2M | 11.6M | |
| Total Stockholder Equity | (3.6K) | 3.4M | (99.5K) | 1.1M | 6.6M | 6.3M | |
| Retained Earnings | (3.6K) | (2.5M) | (14.5M) | (25.3M) | (25.5M) | (24.2M) | |
| Accounts Payable | 1.6M | 865.9K | 596.3K | 554.2K | 1.4M | 812.7K | |
| Cash | 147.1M | 4.5M | 1.3M | 5.3M | 12.0M | 11.4M | |
| Short Term Investments | 163.2M | 187.6M | 185.7M | 525.3K | 472.8K | 449.1K | |
| Total Liab | 26.3K | 1.2M | 2.1M | 4.5M | 5.6M | 5.3M | |
| Total Current Liabilities | 26.3K | 1.2M | 2.1M | 4.5M | 5.6M | 5.3M | |
| Other Liab | 5.9M | 8.0M | 76.4M | 50.7M | 58.3M | 32.4M | |
| Net Tangible Assets | 234.4M | 273.9M | 3.0M | (7.8M) | (7.0M) | (6.7M) | |
| Other Current Assets | 7.7M | 128K | 637.3K | 73.1K | 155.8K | 148.0K | |
| Other Stockholder Equity | 1.1M | 5.5M | 14.4M | 26.4M | 32.1M | 33.7M | |
| Total Current Assets | 154.8M | 4.6M | 1.9M | 5.4M | 12.1M | 11.5M | |
| Common Stock | 60.1M | 2.3K | 2.3K | 683.0 | 265.0 | 251.75 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (17.53) | Return On Assets (0.51) | Return On Equity (2.70) |
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.